Key facts
- Molecule: semaglutide, a 31-amino-acid GLP-1 receptor agonist derived from human GLP-1 with a fatty-acid chain that extends its half-life to about a week.
- Brand owner: Novo Nordisk. Ozempic, Wegovy, and Rybelsus are all semaglutide under different labels.
- Approval status: FDA-approved (December 2017) for type 2 diabetes; expanded in 2020 to cardiovascular risk reduction in type 2 diabetes with known heart disease; expanded again in January 2025 to slowing chronic kidney disease progression.
- Route: subcutaneous injection, once weekly, from a multi-dose pen.
- Highest labeled strength: 2 mg per week — below Wegovy's 2.4 mg.
- Evidence level: very strong. Dozens of randomized phase 3 trials (the SUSTAIN program) plus two large cardiovascular and kidney outcome trials with tens of thousands of participants.
- Commonly reported side effects: nausea, vomiting, diarrhea, constipation, abdominal pain; labeled warnings for pancreatitis, gallbladder disease, and rodent thyroid C-cell tumors.
- Legal status: prescription-only in the US, UK, EU, Canada, and Australia. Not a controlled substance, but not legally obtainable without a prescriber.
What is Ozempic?
Ozempic is a brand name for semaglutide, a once-weekly injectable drug from Novo Nordisk. Semaglutide is a modified version of human glucagon-like peptide-1, a gut hormone released after eating. The natural hormone is destroyed within minutes; semaglutide's engineered backbone and attached fatty-acid chain let it bind albumin in the blood and survive for roughly a week, which is why one injection covers seven days.
The name confusion is worth clearing up immediately. Ozempic, Wegovy, and Rybelsus are three products containing the same active ingredient. They differ in what the FDA has approved them to treat, how they are taken, and their highest labeled strength. If you want the molecule rather than the marketing, read our overview of semaglutide. If you only care about the brand distinction, skip to Ozempic vs Wegovy.
Ozempic reached the US market in early 2018 and became one of the most prescribed drugs in the world within five years. Its cultural moment came from something that was never on its label: people without diabetes taking it to lose weight.
How does Ozempic work?
GLP-1 is released by intestinal L-cells in response to food and does several things at once, mapped out in detail in the physiology literature on glucagon-like peptide 1. It amplifies insulin release from pancreatic beta cells, but only when blood glucose is elevated — which is why GLP-1 drugs rarely cause hypoglycemia on their own. It suppresses glucagon, the hormone that tells the liver to dump stored glucose. It slows gastric emptying, so a meal leaves the stomach more gradually. And it acts on receptors in the hypothalamus and brainstem that register satiety.
Semaglutide reproduces all four effects continuously rather than in post-meal bursts. The glucose-lowering comes mainly from the insulin and glucagon effects; the weight loss comes mainly from delayed gastric emptying and central appetite suppression. People on it commonly describe reduced "food noise" — the background hum of thinking about eating — rather than nausea-driven avoidance. Our primer on the GLP-1 agonist drug class covers how the different molecules in this family diverge.
Is Ozempic FDA approved, and for what?
Yes, and the label has grown three times:
- December 2017: approved to improve glycemic control in adults with type 2 diabetes, alongside diet and exercise.
- January 2020: approved to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, non-fatal stroke — in adults with type 2 diabetes and established cardiovascular disease.
- January 2025: approved to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, on the strength of the FLOW trial.
Weight loss is conspicuously absent from that list. Ozempic has never been approved as a weight-management drug in the US. Prescribing it to a patient without type 2 diabetes for weight loss is off-label — legal for a physician to do, but outside the studied indication and usually outside insurance coverage.
Ozempic vs Wegovy: same drug, different label
This is the single most searched question about Ozempic, and the answer is simpler than the internet makes it. Ozempic and Wegovy contain identical semaglutide molecules from the same manufacturer. The differences are regulatory and practical:
- Indication. Ozempic is a diabetes and cardiorenal drug. Wegovy is a chronic weight management drug, approved in 2021 for adults with obesity or overweight plus a weight-related condition, and later for adolescents aged 12 and up. In March 2024 Wegovy also gained an indication for cardiovascular risk reduction in adults with overweight or obesity and established heart disease.
- Highest labeled strength. Ozempic stops at 2 mg weekly. Wegovy goes to 2.4 mg. That gap looks trivial and is not: the weight-loss trials that made semaglutide famous used 2.4 mg.
- Pen design. Ozempic uses a multi-dose pen; Wegovy has been supplied as single-dose pens.
- Coverage and price. Diabetes and weight management sit in different formulary buckets, and many US plans that cover Ozempic for diabetes exclude Wegovy for weight.
Semaglutide's third form, Rybelsus, is a daily tablet approved for type 2 diabetes. In December 2025 the FDA approved an oral 25 mg semaglutide tablet marketed as the Wegovy pill for chronic weight management — the first oral GLP-1 approved for weight loss.
| Brand | Molecule | Maker | FDA-approved for | Form | Highest labeled strength |
|---|---|---|---|---|---|
| Ozempic | Semaglutide | Novo Nordisk | Type 2 diabetes; cardiovascular risk reduction in T2D with heart disease; chronic kidney disease in T2D | Weekly injection | 2 mg / week |
| Wegovy | Semaglutide | Novo Nordisk | Chronic weight management; cardiovascular risk reduction in overweight or obesity with heart disease | Weekly injection | 2.4 mg / week |
| Rybelsus | Semaglutide | Novo Nordisk | Type 2 diabetes | Daily tablet | 14 mg / day |
| Wegovy pill | Semaglutide | Novo Nordisk | Chronic weight management (approved December 2025) | Daily tablet | 25 mg / day |
| Mounjaro | Tirzepatide | Eli Lilly | Type 2 diabetes | Weekly injection | 15 mg / week |
| Zepbound | Tirzepatide | Eli Lilly | Chronic weight management; obstructive sleep apnea in obesity | Weekly injection | 15 mg / week |
Does Ozempic actually work?
For what it was approved to do, the evidence is about as good as modern pharmacology gets.
Blood sugar. The head-to-head SUSTAIN 7 trial randomized 1,201 people with type 2 diabetes to semaglutide or dulaglutide for 40 weeks. Semaglutide 1 mg lowered HbA1c by 1.8 percentage points against 1.4 for dulaglutide 1.5 mg, and cut body weight by 6.5 kg against 3.0 kg. SUSTAIN FORTE later compared semaglutide 2 mg with 1 mg in 961 people with poorly controlled diabetes: HbA1c fell 2.2 versus 1.9 percentage points, weight fell 6.9 versus 6.0 kg. A broader review of head-to-head GLP-1 studies places semaglutide at the top of the injectable GLP-1 class for glycemic effect.
Hearts. SUSTAIN-6 enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk and followed them for just over two years. The composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke occurred in 6.6% on semaglutide versus 8.9% on placebo — a hazard ratio of 0.74. That trial is the basis of the cardiovascular indication.
Kidneys. The FLOW trial, published in 2024, tested semaglutide in 3,533 people with type 2 diabetes and chronic kidney disease. Major kidney events were reduced by 24% (hazard ratio 0.76), and the trial was stopped early for efficacy. This is what produced the 2025 label expansion.
Notably, the cardiovascular benefit extends beyond diabetes. The SELECT trial gave semaglutide 2.4 mg to 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes, and found a 20% reduction in major cardiovascular events over a mean 3.3 years. That trial used the Wegovy strength, not the Ozempic one.
How much weight do people lose on Ozempic?
Less than the headlines imply, because the headlines are usually about Wegovy. Within diabetes trials, semaglutide at Ozempic strengths produced roughly 6 to 7 kg of weight loss over 40 weeks — meaningful, but not transformative.
The dramatic numbers come from the higher-dose program. STEP 1 randomized 1,961 adults with overweight or obesity and no diabetes to semaglutide 2.4 mg weekly or placebo for 68 weeks. Mean weight change was −14.9% versus −2.4%, or about 15.3 kg versus 2.6 kg. STEP 8 compared it directly against liraglutide 3.0 mg and reported −15.8% versus −6.4% at 68 weeks.
Two caveats matter. First, people with type 2 diabetes consistently lose less weight on GLP-1 drugs than people without it. Second, some of the loss is lean tissue. A network meta-analysis of GLP-1 effects on body composition across 22 randomized trials found lean mass accounted for roughly 25% of total weight lost, with semaglutide 2.4 mg and tirzepatide 15 mg among the most effective for fat loss and the least effective at preserving lean mass — though relative lean mass as a percentage of body weight was unchanged.
How long does Ozempic take to work?
Different endpoints move on different clocks. Semaglutide reaches steady blood concentrations after roughly four to five weeks at a fixed weekly strength, and glucose effects appear within the first weeks. Weight is far slower: in STEP 1 the weight curve kept descending for close to a year before flattening near week 60. Anyone evaluating results at week 6 is looking at the appetite effect, not the outcome.
Trials also escalate the dose in steps over several months rather than starting at the target strength, specifically because gastrointestinal side effects cluster at each increase. That is one reason accurate records of when each change happened are more useful than they look — see how to track injectable medications.
Ozempic side effects reported in trials
The dominant category is gastrointestinal, and it is not subtle. In SUSTAIN 7, gastrointestinal disorders were reported by 43% of participants on semaglutide 0.5 mg and 44% on 1 mg, and were the leading cause of discontinuation. In placebo-controlled diabetes trials described in the US label, nausea occurred in roughly 16% of participants on 0.5 mg and 20% on 1 mg, against about 6% on placebo. Most of it concentrates in the first weeks and after each dose increase, then subsides for the majority of people.
Beyond nausea, a widely cited 2023 JAMA analysis of gastrointestinal adverse events in people using GLP-1 drugs for weight loss found elevated risks of pancreatitis, bowel obstruction, and gastroparesis compared with an older weight-loss drug. The absolute event rates were low and the design was observational, but it prompted label attention and, separately, anesthesia guidance about retained stomach contents before surgery.
Labeled warnings include acute pancreatitis, gallbladder disease, acute kidney injury from dehydration during vomiting, hypoglycemia when combined with insulin or sulfonylureas, worsening of diabetic retinopathy, and a boxed warning about thyroid C-cell tumors observed in rodents — a finding of unknown relevance to humans, but enough to contraindicate semaglutide in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
An eye signal emerged in 2024, when a matched cohort study at Massachusetts Eye and Ear reported a higher rate of nonarteritic anterior ischemic optic neuropathy among patients prescribed semaglutide (hazard ratio 4.28 in the diabetes group). A 2026 systematic review and meta-analysis of 8 randomized trials and 8 observational studies put this in perspective: the absolute rate was about 26.7 versus 18.9 NAION cases per 100,000 person-years in diabetes, the observational signal held (hazard ratio 1.85) but the randomized trials did not confirm it, and no increased risk appeared in weight-loss populations. Real but rare, and still unsettled.
What is "Ozempic face"?
"Ozempic face" describes the hollow cheeks, deepened folds, and generally aged appearance some people develop after fast weight loss on semaglutide. A 2025 systematic review in the plastic surgery literature examined 23 publications and concluded these are morphological changes from losing facial fat volume — the same thing that happens with rapid weight loss from any cause — rather than a distinct pharmacological effect on skin or facial tissue. The review also documented the search-traffic link between "Ozempic face" and rising interest in fillers and plastic surgeons.
The practical version: the faster and larger the weight loss, and the older the person, the more visible it is. Facial fat pads do not regenerate on their own, which is why the effect is only partially reversible.
What happens when you stop Ozempic?
Weight comes back. The one-year extension of STEP 1 followed participants after both semaglutide and the lifestyle intervention were withdrawn. They regained roughly two-thirds of the weight they had lost, and improvements in blood pressure, lipids, and glycemic markers moved back toward baseline alongside it.
That result is often reported as a failure of the drug. It is more accurately a description of what obesity pharmacotherapy is: treatment of a chronic condition, effective while taken, like an antihypertensive. Blood sugar behaves the same way — semaglutide does not remodel the pancreas, and glucose control drifts back after discontinuation.
Ozempic vs Mounjaro and other GLP-1 drugs
The direct rival is tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight. Tirzepatide activates both the GLP-1 and GIP receptors rather than GLP-1 alone. In SURMOUNT-5, the first head-to-head weight-loss trial between them, tirzepatide produced 20.2% weight loss against 13.7% for semaglutide 2.4 mg over 72 weeks. For a fuller breakdown see Mounjaro vs Ozempic, Mounjaro, and tirzepatide.
Older GLP-1 options include liraglutide (daily injection, weaker effect) and dulaglutide. Further out are triple agonists still in development — see peptides studied for weight loss for where the field is heading.
Shortages, compounded semaglutide, and counterfeits
Demand outran supply for much of 2022 through 2024, and semaglutide sat on the FDA drug shortage list. That listing temporarily allowed compounding pharmacies to prepare semaglutide products, and a large telehealth market grew around them. When the shortage was formally resolved in early 2025, that legal basis narrowed sharply.
Compounded semaglutide is not the same product as Ozempic. A 2026 analysis in Annals of Pharmacotherapy examining compounded semaglutide and tirzepatide products found they frequently use unique formulations and salt forms whose efficacy and safety data are largely unknown. Separately, the FDA has warned about dosing errors from users drawing doses out of multi-dose vials, and about counterfeit Ozempic pens entering the legitimate supply chain. Anything sold online as "research-grade" semaglutide is outside the pharmacy system entirely — see the legal status of peptides for how that category actually works.
What Ozempic costs and what insurance covers
US list price for Ozempic has sat around $900 to $1,000 per month without insurance, with Wegovy higher. Actual cost depends almost entirely on coverage, and coverage depends on the indication on the prescription. Plans that pay for Ozempic in type 2 diabetes routinely reject the same molecule for weight management, and many require documented failure of cheaper agents like metformin first. Medicare is prohibited from covering drugs prescribed solely for weight loss, though coverage exists when a cardiovascular indication applies.
Outside the US, prices are typically a fraction of the American figure, which is why cross-border purchasing became common. Prices shift frequently; treat any figure you read, including this one, as approximate and check current pricing directly.
Tracking a weekly injection properly
A once-weekly drug with a months-long titration schedule is exactly the kind of medication people lose track of. The questions that come up at follow-up appointments are consistently the same: which day was the last injection, when did the strength change, which site was used last, and did the nausea cluster around a particular week. Those answers live in a log or they do not exist.
That is what PepMate is for. It keeps the record; your clinician makes the decisions.
Frequently asked questions
Is Ozempic the same as Wegovy?
Both are semaglutide, made by Novo Nordisk. Ozempic carries FDA indications for type 2 diabetes, cardiovascular risk reduction, and chronic kidney disease, and its label tops out at 2 mg weekly. Wegovy carries the chronic weight management indication and goes to 2.4 mg weekly. Same molecule, different label, different maximum strength, and very different insurance treatment.
Is Ozempic FDA approved for weight loss?
No. Ozempic's approvals cover blood sugar control in type 2 diabetes, reduction of major cardiovascular events in adults with type 2 diabetes and established heart disease, and slowing kidney disease progression in type 2 diabetes with chronic kidney disease. Prescribing it purely for weight loss is off-label use. Wegovy is the semaglutide brand that carries the weight management indication.
Does Ozempic actually work?
For its approved uses, yes, and the evidence is unusually strong. In SUSTAIN 7, semaglutide 1 mg cut HbA1c by 1.8 percentage points versus 1.4 for dulaglutide 1.5 mg over 40 weeks. In SUSTAIN-6, it reduced the combined risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke by 26 percent over about two years.
How much weight do people lose on Ozempic?
In diabetes trials, semaglutide 1 mg produced roughly 6.5 kg of weight loss at 40 weeks and 2 mg roughly 6.9 kg. Higher-dose semaglutide 2.4 mg, sold as Wegovy, produced 14.9 percent of body weight over 68 weeks in the STEP 1 trial. People with type 2 diabetes generally lose less weight than people without it.
What are the most common Ozempic side effects?
Gastrointestinal ones. Nausea, vomiting, diarrhea, and constipation dominate the adverse-event tables in every semaglutide trial and are the most common reason people stop. In SUSTAIN 7, gastrointestinal disorders affected 43 to 44 percent of semaglutide participants. Labeled warnings also cover pancreatitis, gallbladder disease, thyroid C-cell tumors seen in rodents, and diabetic retinopathy complications.
What is Ozempic face?
Ozempic face is the hollowed, prematurely aged look some people develop after fast weight loss on a GLP-1 drug. A 2025 systematic review of the plastic surgery literature concluded the change comes from losing facial fat volume during rapid weight loss rather than from a unique action of semaglutide. It is more noticeable in older people and with faster loss.
Do you regain weight after stopping Ozempic?
Usually. In the STEP 1 extension study, participants regained about two-thirds of the weight they had lost during the year after semaglutide and lifestyle support were withdrawn, and improvements in blood pressure and lipids drifted back toward baseline. Semaglutide has been studied as continuing therapy, not as a short course.
How long does Ozempic take to work?
Blood sugar starts moving within the first few weeks, and semaglutide reaches steady blood levels after roughly four to five weeks at a given weekly strength. Weight change is much slower. In STEP 1 the weight curve did not level off until around week 60, so judging results before several months is premature.
Is compounded semaglutide the same as Ozempic?
No. Compounded semaglutide is not an FDA-approved product and is not held to the same manufacturing review as Ozempic. A 2026 pharmacy analysis found compounded semaglutide and tirzepatide products frequently use unique formulations and salt forms whose efficacy and safety are largely unknown. Dosing errors and counterfeit pens have both been reported.
Can you buy Ozempic without a prescription?
Not legally. Semaglutide is prescription-only in the United States, United Kingdom, European Union, Canada, and Australia. Vials sold online as research-grade semaglutide are unapproved products with no verified identity, sterility, or strength, and they sit outside the pharmacy supply chain entirely. Only a licensed prescriber can legally provide Ozempic.
Sources
Every claim above traces to peer-reviewed literature indexed on PubMed:
- The physiology of glucagon-like peptide 1 — PubMed 17928588
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial — PubMed 29397376
- Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE) — PubMed 34293304
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes — PubMed 27633186
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes — PubMed 38785209
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes — PubMed 37952131
- Once-Weekly Semaglutide in Adults with Overweight or Obesity — PubMed 33567185
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial — PubMed 35015037
- Weight regain and cardiometabolic effects after withdrawal of semaglutide — PubMed 35441470
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — PubMed 40353578
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMed 33767808
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss — PubMed 37796527
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide — PubMed 38958939
- Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss: A Systematic Review and Meta-Analysis — PubMed 41475544
- "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions — PubMed 40626110
- Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis — PubMed 39719170
- Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown — PubMed 41689811
Approval dates and label warnings reflect FDA prescribing information for Ozempic and Novo Nordisk regulatory announcements. Prices and coverage rules change frequently — verify current figures directly.